Identifying FLT3 Mutations in AML

Virtual Event:

Identifying FLT3 Mutations in Acute Myeloid Leukemia (AML) to Inform Clinical Decision-making – A Focus on Relapsed/Refractory Disease

No continuing education (CE) or continuing medical education (CME) credit can be provided for this presentation sponsored by Astellas Pharma US, Inc.

PRESENTER
Catherine Lai, M.D., M.P.H.
Medstar Georgetown University Hospital ; Lombardi Comprehensive Cancer Center ; Georgetown University Medical Center
Washington, DC

*Important note: Attendees are required to view the presented slides during the virtual program

To RSVP for this program – Please contact:

Melba Vasquez
melba.vasquez@astellas.com

Or go to: https://astellas.virtualspeakercast.net/Registration/index/236

Kindly reply by March 23, 2021

In the RSVP, please include your name, contact information, organization, and specialty.